179 related articles for article (PubMed ID: 9204393)
1. Quantitative structure-activity relationship studies on anti-HIV-1 TIBO derivatives as inhibitors of viral reverse transcriptase.
Gupta SP; Garg R
J Enzyme Inhib; 1996 Aug; 11(1):23-32. PubMed ID: 9204393
[TBL] [Abstract][Full Text] [Related]
2. Quantitative structure-activity relationship studies on some anti-human-immunodeficiency-virus-1 (anti-HIV-1) drugs: viral reverse transcriptase inhibitors.
Garg R; Gupta SP
J Enzyme Inhib; 1997 Apr; 12(1):1-12. PubMed ID: 9204378
[TBL] [Abstract][Full Text] [Related]
3. From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
De Corte BL
J Med Chem; 2005 Mar; 48(6):1689-96. PubMed ID: 15771411
[No Abstract] [Full Text] [Related]
4. Relative free energy of binding and binding mode calculations of HIV-1 RT inhibitors based on dock-MM-PB/GS.
Zhou Z; Madura JD
Proteins; 2004 Nov; 57(3):493-503. PubMed ID: 15382241
[TBL] [Abstract][Full Text] [Related]
5. Data mining using template-based molecular docking on tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone (TIBO) derivatives as HIV-1RT inhibitors.
Sapre NS; Gupta S; Pancholi N; Sapre N
J Mol Model; 2008 Nov; 14(11):1009-21. PubMed ID: 18642033
[TBL] [Abstract][Full Text] [Related]
6. Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms.
Li D; Zhan P; De Clercq E; Liu X
J Med Chem; 2012 Apr; 55(8):3595-613. PubMed ID: 22268494
[No Abstract] [Full Text] [Related]
7. Hologram quantitative structure-activity relationships investigations of non-nucleoside reverse transcriptase inhibitors.
Pungpo P; Hannongbua S; Wolschann P
Curr Med Chem; 2003 Sep; 10(17):1661-77. PubMed ID: 12871115
[TBL] [Abstract][Full Text] [Related]
8. Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
Debyser Z; Vandamme AM; Pauwels R; Baba M; Desmyter J; De Clercq E
J Biol Chem; 1992 Jun; 267(17):11769-76. PubMed ID: 1376311
[TBL] [Abstract][Full Text] [Related]
9. Support vector machines: development of QSAR models for predicting anti-HIV-1 activity of TIBO derivatives.
Darnag R; Mostapha Mazouz EL; Schmitzer A; Villemin D; Jarid A; Cherqaoui D
Eur J Med Chem; 2010 Apr; 45(4):1590-7. PubMed ID: 20110136
[TBL] [Abstract][Full Text] [Related]
10. Molecular docking studies on tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone (TIBO) derivatives as HIV-1 NNRT inhibitors.
Sapre NS; Gupta S; Pancholi N; Sapre N
J Comput Aided Mol Des; 2008 Feb; 22(2):69-80. PubMed ID: 18163186
[TBL] [Abstract][Full Text] [Related]
11. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
Mellors JW; Im GJ; Tramontano E; Winkler SR; Medina DJ; Dutschman GE; Bazmi HZ; Piras G; Gonzalez CJ; Cheng YC
Mol Pharmacol; 1993 Jan; 43(1):11-6. PubMed ID: 7678690
[TBL] [Abstract][Full Text] [Related]
12. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
Das K; Ding J; Hsiou Y; Clark AD; Moereels H; Koymans L; Andries K; Pauwels R; Janssen PA; Boyer PL; Clark P; Smith RH; Kroeger Smith MB; Michejda CJ; Hughes SH; Arnold E
J Mol Biol; 1996 Dec; 264(5):1085-100. PubMed ID: 9000632
[TBL] [Abstract][Full Text] [Related]
13. Colorimetric assays for evaluation of the mode of action of human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors.
Shao X; Rytting AS; Ekstrand DH; Vrang L; Källander CF; Gronowitz JS
Antivir Chem Chemother; 1998 Mar; 9(2):167-76. PubMed ID: 9875388
[TBL] [Abstract][Full Text] [Related]
14. Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis.
de Vreese K; Debyser Z; Vandamme AM; Pauwels R; Desmyter J; de Clercq E; Anné J
Virology; 1992 Jun; 188(2):900-4. PubMed ID: 1374986
[TBL] [Abstract][Full Text] [Related]
15. Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase--structure-activity relationships and crystallographic analysis.
Kirschberg TA; Balakrishnan M; Huang W; Hluhanich R; Kutty N; Liclican AC; McColl DJ; Squires NH; Lansdon EB
Bioorg Med Chem Lett; 2008 Feb; 18(3):1131-4. PubMed ID: 18083512
[TBL] [Abstract][Full Text] [Related]
16. QSAR modeling with the electrotopological state: TIBO derivatives.
Huuskonen J
J Chem Inf Comput Sci; 2001; 41(2):425-9. PubMed ID: 11277732
[TBL] [Abstract][Full Text] [Related]
17. Structural flexibility of non-nucleoside HIV-1 reverse transcriptase inhibitor: 9-Cl TIBO as explained by potential energy surface and (13)C and (1)H NMR calculations, based on ab initio and density functional study.
Saen-Oon S; Hannongbua S; Wolschann P
J Chem Inf Comput Sci; 2003; 43(5):1412-22. PubMed ID: 14502474
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and anti-HIV activity of 1,3,4,5-tetrahydro-2H-1,4-benzodiazepin-2-one (TBO) derivatives. Truncated 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2( 1H)-on es (TIBO) analogues.
Breslin HJ; Kukla MJ; Kromis T; Cullis H; De Knaep F; Pauwels R; Andries K; De Clercq E; Janssen MA; Janssen PA
Bioorg Med Chem; 1999 Nov; 7(11):2427-36. PubMed ID: 10632052
[TBL] [Abstract][Full Text] [Related]
19. Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives.
Esnouf RM; Stuart DI; De Clercq E; Schwartz E; Balzarini J
Biochem Biophys Res Commun; 1997 May; 234(2):458-64. PubMed ID: 9177293
[TBL] [Abstract][Full Text] [Related]
20. Predictive QSAR modeling of HIV reverse transcriptase inhibitor TIBO derivatives.
Mandal AS; Roy K
Eur J Med Chem; 2009 Apr; 44(4):1509-24. PubMed ID: 18760864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
